Efficacy and Safety Observation of Febuxostat in the Treatment of Maintenance Peritoneal Dialysis Patients Complicated with Gout

OBJECTIVE To explore the curative effect and safety of febuxostat in the treatment of maintenance peritoneal dialysis patients complicated with gout. METHODS Forty-six maintenance peritoneal dialysis patients complicated with gout were enrolled in Fujian Provincial Hospital Jinshan Branch from May 2016 to May 2019. All the patients were divided into the experimental group treated with febuxostat and the control group treated with allopurinol for 6 months. The serum uric acid, liver function, cardiac troponin I as well as the incidence of adverse reactions and the number of recurrence of gout were observed and compared between two groups in the treatment period. RESULTS The levels of serum uric acid in two groups were decreased after treatment, moreover, the concentration of serum uric acid in the experimental group were significantly lower than those in the control group(P<0.05). In addition the effective rates of the experimental group were higher than those in the control group(P<0.05). There was no significant difference in liver function and cardiovascular events among the two groups. However, the number of acute gout attack in the experimental group was higher than that in the control group in the early stage of uric lowering therapy(P<0.05). CONCLUSION Compared with allopurinol, febuxostat has better clinical effect in treatment of patients undergoing maintenance peritoneal dialysis complicated with gout, which can obviously reduce the levels of serum uric acid with little adverse reactions and may have a certain clinical application value.